ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,970.84
      -1.11%
      US Tech 100
      20,865.20
      -0.18%
      Dow Jones
      42,992.21
      -0.77%
      Brent Oil
      73.845
      0.30%
      Bitcoin
      93,764.34
      0.26%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE

      6. Arcus Biosciences Inc (RCUS) Quote

      Arcus Biosciences Inc

      Arcus Biosciences Inc (RCUS)

      NYSE
      15.27
      -0.56
      (-3.54%)
      Closed December 27 4:00PM
      Delayed by 15 minutes
      15.27
      0.00
      ( 0.00% )
      Pre Market: 4:00AM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      15.27
      Bid
      -
      Ask
      -
      Volume
      2
      0.00 Day's Range 0.00
      13.52 52 Week Range 20.31
      Market Cap
      1.397B
      Previous Close
      15.27
      Open
      -
      Last Trade
      1
      @
      16.39
      Last Trade Time
      05:50:18
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      776,195
      Shares Outstanding
      91,511,609
      Dividend Yield
      -
      PE Ratio
      -4.55
      Earnings Per Share (EPS)
      -3.35
      Revenue
      117M
      Net Profit
      -307M

      About Arcus Biosciences Inc

      Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.arcusbio.com
      Headquarters
      Camden, Delaware, USA
      Founded
      -
      Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was $15.27. Over the last year, Arcus Biosciences shares have traded in a share price range of $ 13.52 to $ 20.31.

      Arcus Biosciences currently has 91,511,609 shares outstanding. The market capitalization of Arcus Biosciences is $1.40 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -4.55.

      Ask ADVFN Intelligence (AI)

      RCUS Latest News

      More News

      Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

      December 24 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      December 20 2024
      Edgar (US Regulatory)

      Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

      Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that...

      December 19 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      December 17 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 17 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      December 17 2024
      Edgar (US Regulatory)

      Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

      December 10 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      December 04 2024
      Edgar (US Regulatory)

      Arcus Biosciences Announces New Employment Inducement Grants

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

      December 03 2024
      Business Wire

      Arcus Biosciences to Participate in Two Upcoming Investor Conferences

      Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that...

      November 19 2024
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.29-1.8637532133715.5616.4714.9439595915.7158204CS
      4-0.05-0.3263707571815.3218.0914.77570519916.32689536CS
      12-1.51-8.9988081048916.7818.9814.1577619516.52325575CS
      260.080.52666227781415.1918.9813.5266228716.20572544CS
      52-3.76-19.758276405719.0320.3113.5272277716.55370992CS
      156-26.78-63.686087990542.0543.5312.9586842121.48835764CS
      2604.5542.444029850710.7249.18.5574991523.77085287CS

      RCUS - Frequently Asked Questions (FAQ)

      What is the current Arcus Biosciences share price?
      The current share price of Arcus Biosciences is $ 15.27
      How many Arcus Biosciences shares are in issue?
      Arcus Biosciences has 91,511,609 shares in issue
      What is the market cap of Arcus Biosciences?
      The market capitalisation of Arcus Biosciences is USD 1.4B
      What is the 1 year trading range for Arcus Biosciences share price?
      Arcus Biosciences has traded in the range of $ 13.52 to $ 20.31 during the past year
      What is the PE ratio of Arcus Biosciences?
      The price to earnings ratio of Arcus Biosciences is -4.55
      What is the cash to sales ratio of Arcus Biosciences?
      The cash to sales ratio of Arcus Biosciences is 11.94
      What is the reporting currency for Arcus Biosciences?
      Arcus Biosciences reports financial results in USD
      What is the latest annual turnover for Arcus Biosciences?
      The latest annual turnover of Arcus Biosciences is USD 117M
      What is the latest annual profit for Arcus Biosciences?
      The latest annual profit of Arcus Biosciences is USD -307M
      What is the registered address of Arcus Biosciences?
      The registered address for Arcus Biosciences is 2140 S DUPONT HWY, KENT, CAMDEN, DELAWARE, 19934
      What is the Arcus Biosciences website address?
      The website address for Arcus Biosciences is www.arcusbio.com
      Which industry sector does Arcus Biosciences operate in?
      Arcus Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      STEMStem Inc
      $ 0.8663
      (45.69%)
      		9.88M
      RMAXRE MAX Holdings Inc
      $ 13.59
      (27.25%)
      		24
      OECOrion SA
      $ 18.99
      (21.19%)
      		23
      TSQTownsquare Media Inc
      $ 11.00
      (17.15%)
      		209
      MATVMativ Holdings Inc
      $ 12.70
      (15.66%)
      		8
      ASIXAdvanSix Inc
      $ 23.01
      (-18.29%)
      		2
      CURBCurbline Properties Corp
      $ 20.01
      (-14.81%)
      		1
      TBNTamboran Resources Corporation
      $ 16.00
      (-14.58%)
      		267
      TGTredegar Corp
      $ 6.71
      (-12.63%)
      		1
      LXFRLuxfer Holdings PLC
      $ 11.51
      (-12.07%)
      		1
      STEMStem Inc
      $ 0.8663
      (45.69%)
      		9.88M
      SESSES AI Corporation
      $ 2.43
      (1.67%)
      		5.36M
      QBTSD Wave Quantum Inc
      $ 9.93
      (0.20%)
      		1.47M
      IONQIonQ Inc
      $ 44.25
      (-2.70%)
      		519.3k
      BBAIBigBear ai Holdings Inc
      $ 4.11
      (-2.38%)
      		451.66k

      RCUS Discussion

      View Posts
      Monksdream Monksdream 3 months ago
      RCUS a buy under $14
      👍️0
      PennyWorld PennyWorld 1 year ago
      https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?ref=biztoc.com
      👍️0
      conix conix 3 years ago
      Biotechs are starting to react to news...finally.
      👍️0
      dinogreeves dinogreeves 5 years ago
      The stock didn't react as well as expected with the partnership, but it did hi almost my price target. This is a partnership 200 million equity investment and 175 million up front payment, which. implies no offering on the table. Makes you wonder why the stock is down, guess people were expecting a buyout. Some of these people are so lame, unbelievable.
      👍️0
      lovetc lovetc 5 years ago
      Also in the DEF 14.....didnt see any information regarding Gilead....
      👍️0
      lovetc lovetc 5 years ago
      shorted some and bought some put at $31 last Friday....Also today when it reached $30 I short.....I find no reason not to short above $30 lol....It will be $18 soon since the Volumn start declined....
      👍️0
      dinogreeves dinogreeves 5 years ago
      RCUS will likely hit 40 this week and if it does that could essentially mean that there is buyout looming from GI*LD. Someone is buying heavy between 27-29 dollars, obviously they don't want it dip more than 26-27 dollars, it could be a number of reasons that is beyond any retails control.
      👍️0
      dinogreeves dinogreeves 5 years ago
      Bought another 1000 shares on that dip, going to wait this one.
      👍️0
      dinogreeves dinogreeves 5 years ago
      Possible huge asset buy, or outright buyout coming from GILD or even a partnership.
      👍️0
      dinogreeves dinogreeves 5 years ago
      RCUS getting ready to pop to 33-35 dollars.
      👍️0
      dinogreeves dinogreeves 5 years ago
      This is my letter to the shorts with margin account


      That is where dummies like you are mistaken. If GILD places anywhere close to that dollar amount this stock jumps over triple digits in less then 2 hours and if there is buyout it won't even let you blink, just one share will it to the buyout price. If GOOGLE has 17% stake on this company and GILD is looking to either buy or take a stake, there must be something that you and I are not aware of the current directors sold their pervious company to Bristol for 1.5 billion dollars. There is more here than meets the eye. I am taking my chance because if no balls no glory and when that happens short margin account will be vaporized.


      https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
      👍️0
      dinogreeves dinogreeves 5 years ago
      If this happens the stock will shoot up to over $200 dollars in an instant. Only if that happens.



      https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
      👍️0
      dinogreeves dinogreeves 5 years ago
      News could come from GI*LD that there is a buyout. Watch for news.
      👍️0

      Your Recent History

      NYSE
      RCUS
      Arcus Biosciences
      BIT
      OSA
      OSAI Automation System
      LSE
      36AU
      Sthn.pac 5a1as
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads